Author(s): Natalia N. Lepkova, Angelina V. Egorova, German D. Anglichaninov and Alexander S. Lepkov
Aim of the Study: The study included 200 women with stage IIB–IIIA MP RG (T2N1M0, T3N0M0, T1N2aM0, T2N2aM, T3N1M0, T3N2aM0). The patients were divided into 2 groups – the main group (n=103) and the control group (n=97). All patients underwent NPHT according to the standard FAC scheme, which includes cyclophosphamide, which is administered at the rate of 500 mg/m2, 5-fluorouracil-500 mg/m2 and doxorubicin-50 mg / m2. Methodology: All patients were examined in full: standard clinical laboratory examinations, x-ray examinations-mammography in direct and lateral projections, axilography, complex ultrasound examination of the breast and breast cancer, computed tomography of the chest and abdominal cavity, pelvis. Conclusion: Patients of the control group were given 4 courses of npht according to the FAC scheme, after which control mammography was performed in order to assess the effect of the therapy and plan further treatment. When a positive effect was detected – a reduction in the size of the primary tumor and/or a reduction in the size of metastatic RLV or stabilization of the process, patients underwent radical surgery. When the primary tumor or metastatic RLV progressed, the patients changed the PCT scheme with subsequent individualization of the treatment plan.